Pfizer study on how atirmociclib levels rise with dose in healthy people
Treatments studied
This trial tests a new cancer drug (atirmociclib) to see how its levels in the body increase when given in different doses. It is for healthy people to help find safe doses for future cancer treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are in good overall health, based on a medical check-up and blood tests.
- Your body mass index (BMI) is between 17.5 and 30.5, and you weigh more than 110 pounds.
- You do not have any significant long-term illness (like heart, liver, or kidney disease) or a history of HIV, hepatitis B, or hepatitis C.
- You have not taken certain medications or substances that affect how the drug is broken down (like strong CYP3A4 or UGT2B7 inducers/inhibitors) in the past month.
- You have never taken atirmociclib or been in another study with this drug.
- You do not have any condition that might change how your body absorbs medication (like stomach or gallbladder surgery).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how a new anti-cancer drug called catequentinib (AL3818) interacts with other medicines in healthy people. It helps researchers understand how the drug is processed in the body.
This Phase 2 study tests abemaciclib, a targeted cancer medicine, in people with advanced solid tumors that have specific gene changes related to cyclin D or CDK4/6. The goal is to see how well it controls tumors when standard treatments don’t work or aren’t available.
This trial tests a new drug (an ATR inhibitor) for people with advanced solid tumors that have not responded to or are not suitable for standard treatments. It aims to see if the drug is safe and effective, and it may be an option if you have good heart function and are feeling well enough to participate.
This study tests how the body handles the medicine Atirmociclib in people with different levels of liver function, from normal to moderate or severe liver disease. It helps doctors understand if the dose needs to be adjusted for people with liver problems.
This trial tests two experimental drugs—camizestrant and atirmociclib—for women with advanced ER-positive breast cancer that has worsened after prior treatment. The goal is to see if the combination is safe and tolerable.
This study tests whether gradually increasing doses of a drug called abemaciclib, combined with hormone therapy, can safely treat early-stage breast cancer that is hormone-positive and HER2-negative. The goal is to find the best dose that works without causing too many side effects.
Hear when a new Healthy Volunteer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.